{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:09Z","timestamp":1761871089129,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clml.2018.05.010","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T12:55:14Z","timestamp":1527080114000},"page":"519-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms"],"prefix":"10.1016","volume":"18","author":[{"given":"Anita","family":"Geevarghese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.05.010_bib1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French\u2013American\u2013British (FAB) Co-operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.010_bib2","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.05.010_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.24396","article-title":"Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.05.010_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2141.1994.tb06733.x","article-title":"Establishing the incidence of myelodysplastic syndrome","volume":"87","author":"Williamson","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.010_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.010_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.mayocp.2015.11.011","article-title":"Chronic myelomonocytic leukemia: focus on clinical practice","volume":"91","author":"Patnaik","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2018.05.010_bib10","first-page":"7","article-title":"The clinical management of chronic myelomonocytic leukemia","volume":"12","author":"Padron","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2018.05.010_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/asheducation-2015.1.349","article-title":"Surveying the landscape of MDS\/MPN research: overlap among the overlap syndromes?","volume":"2015","author":"Padron","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2018.05.010_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.010_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic\u2013French Consortium study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.05.010_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib15","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib16","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.010_bib17","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: Asxl1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.010_bib18","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib19","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.010_bib20","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-14-0739","article-title":"TET2 mutations affect non-Cpg island DNA methylation at enhancers and transcription factor\u2013binding sites in chronic myelomonocytic leukemia","volume":"75","author":"Yamazaki","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.05.010_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4161\/epi.7.2.19015","article-title":"Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia","volume":"7","author":"Yamazaki","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.clml.2018.05.010_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2018.05.010_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"TET2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2018.05.010_bib24","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patniak","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.05.010_bib25","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI67266","article-title":"Isocitrate dehydrogenase mutations in leukemia","volume":"123","author":"McKenney","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2018.05.010_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.010_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.05.010_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.010_bib29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41408-017-0004-0","article-title":"ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS","volume":"7","author":"Sallman","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.05.010_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.05.010_bib31","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.010_bib32","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib33","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.010_bib35","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.010_bib36","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib37","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2018.05.010_bib39","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.010_bib40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.05.010_bib42","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.05.010_bib43","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib44","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.05.010_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ades","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.05.010_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A\u00a0phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.010_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"92","author":"Alfonso","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.05.010_bib48","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood.V74.5.1472.1472","article-title":"Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells","volume":"74","author":"Everson","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib49","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0301-472X(02)00903-7","article-title":"Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in\u00a0vitro and in\u00a0vivo","volume":"30","author":"Ramshaw","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2018.05.010_bib50","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF\u2013dependent Pstat5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib51","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A\u00a0multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.05.010_bib52","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1999.17.3.1071","article-title":"RAS and leukemia: from basic mechanisms to gene-directed therapy","volume":"17","author":"Beaupre","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.010_bib53","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","article-title":"A\u00a0multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome","volume":"109","author":"Fenaux","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib54","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.05.010_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V128.22.966.966","article-title":"H3B-8800, an orally bioavailable modulator of the Sf3b complex, shows efficacy in spliceosome-mutant myeloid malignancies","volume":"128","author":"Buonamici","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib56","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2018.05.010_bib57","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2014.03.022","article-title":"Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis","volume":"38","author":"Buckstein","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.05.010_bib58","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study Swog S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.010_bib59","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2018.05.010_bib60","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.clml.2016.02.009","article-title":"Eltrombopag use in patients with chronic myelomonocytic leukemia (CMML): a cautionary tale","volume":"16","author":"Ramadan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.05.010_bib61","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11899-017-0408-8","article-title":"Therapy for chronic myelomonocytic leukemia in a new era","volume":"12","author":"Moyo","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2018.05.010_bib62","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.010_bib63","unstructured":"MDS Foundation. MDS\/MPN International Working Group. MDS News 2017; 23:26."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:21Z","timestamp":1761870621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018301058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2152265018301058"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}